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Abstract
Globally, an estimated 3.4 million children are living with HIV, yet little is known about the effects of HIV and antiretroviral
treatment (ART) on the developing brain, and the neurodevelopmental and behavioural outcomes of perinatally HIV-infected
(PHIV) adolescents.
We reviewed the literature on neurodevelopmental outcomes in PHIV children and adolescents, and summarized the current
evidence on behaviour, general cognition, specific domains, hearing and language, school performance and physical disabilities
due to neurological problems.
Evidence suggests that PHIV children do not perform as well as controls on general cognitive tests, processing speed and
visualspatial tasks, and are at much higher risk for psychiatric and mental health problems. Children with AIDS-defining
diagnoses are particularly at risk for poorer outcomes.
A striking finding is the lack of published data specific to the adolescent age group (1025 years), particularly from resource-
constrained countries, which have the highest HIV prevalence. In addition, extreme heterogeneity in terms of timing and source
of infection, and antiretroviral experience limits our ability to summarize findings of studies and generalize results to other
settings.
Due to the complex nature of the developing adolescent brain, environmental influences and variation in access to ART, there
is an urgent need for research on the longitudinal trajectory of neurodevelopment among children and adolescents perinatally
infected with HIV, especially in high burden resource-constrained settings.
Keywords: adolescents; children; perinatally HIV infected; neurodevelopment; neurocognitive; neurological; hearing;
executive function.
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Introduction
An estimated 3.4 million children are living with HIV world-
wide [1], 28% of whom have started antiretroviral therapy
(ART) [2]. Yet, little is known about the effects of HIV and ART
on the developing brain and the neurodevelopmental out-
comes of perinatally HIV-infected (PHIV) adolescents.
In neuropsychological terms, adolescence spans the age
range of 1025 years [3], which in 2013 includes those
born between 1988 and 2003. Over this time period, the
management of PHIV infants, children and adolescents
changed dramatically. Before the introduction of ART in 1995,
50% of PHIV children died before the age of two [4], with a
few slow progressors surviving to adolescence [5]. Prior to
1997, children in Europe and the United States may have
received multiple antiretroviral regimens, including those
that would now be considered suboptimal therapy. In 1997,
combination ART was introduced in the United States. Since
2004, access to ART has expanded rapidly in resource-poor
settings and depending on the country, 2880% of treat-
ment-eligible children have initiated ART [2].
Context-specific differences in access to ART over the past
two decades have resulted in great variability in disease
severity and in exposure to ART among PHIV adolescents:
some started ART soon after HIV infection, prior to clinical
diagnosis of neurodevelopmental delay [6]; some initiated
ART after the diagnosis of HIV encephalopathy [7,8], resulting
in neurological deficits that remained permanent despite
ART [9,10]; other PHIV adolescents are slow progressors
and remain ART-naı¨ve as they have not yet reached the ART
eligibility threshold [2]. The source and time of infection
cannot always be determined in HIV adolescents, espe-
cially in settings with generalized HIV epidemics.
There is also substantial heterogeneity in the literature
in terms of the age of study participants. Most published
studies have focused on younger children aged 612 years
[1113] or 716 years [14], crossing from childhood to ado-
lescence. The issue is further compounded by the measures
used to assess functionally relevant outcomes for PHIV
adolescents in diverse cultural settings. In some settings,
the emphasis may be on achieving good school grades to
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maximize employment options, while in other settings
adolescents may be more concerned about starting a family
and providing resources to support a household or extended
family.
Given this extreme heterogeneity in the age of study
participants, severity of disease, antiretroviral experience,
and the definition and measurement of outcomes, we
reviewed the literature on neurodevelopmental outcomes
in PHIV adolescents.
We conducted a literature search using the following key
words: neurodevelopment/al, development, neurocognitive,
cognitive, adolescents, youth, perinatal/vertical HIV-infected,
HIV exposed, school performance, adaptive functioning,
hearing and neuroimaging. We reviewed bibliographies and
relevant articles from different contexts globally, limited
to the most recent papers. We included all ages spanning
adolescence. The original aim was to review evidence on
neurodevelopmental outcomes among perinatally HIV-
infected adolescents. However, the paucity of strictly adoles-
cent data was striking. In the absence of these data, we drew
on published studies of neurodevelopmental in younger
children with HIV as a guide to what could be expected to
impair neurodevelopment in adolescence.
Neurodevelopmental changes during
adolescence
The key developmental tasks during adolescence are to
develop an identity, to become more independent, and to
consider the future in terms of career, relationships, families,
housing, etc. [15]. Traditionally, adolescence is viewed as the
age when abstract thought develops, together with improve-
ments in memory, language, processing speed, attention
and concentration [16]. A more contemporary view is that
the major dimensions of cognitive development during
adolescence are the refinement of executive control and
the attainment of a more conscious, self-directed and self-
regulating mind [1719]. Central to these are executive
function (EF) processes such as voluntary response inhibi-
tion, working memory, response planning, improved proces-
sing speed, cognitive flexibility, and rule-guided behaviour
[18,19].
While the adolescent’s brain does not increase substan-
tially in volume, changes in maturation reflect reorganization
of regulatory systems and correlate with neurocognitive and
behavioural outcomes [17]. During adolescence, white mat-
ter increases in a linear fashion with increased myelination
and re-organization with synaptogenesis and pruning, espe-
cially in the frontal lobes and prefrontal cortex, which serve
as the governor of cognition and action [17,18]. Maturational
changes are influenced by numerous factors including
genetic and environmental factors as well as overall health
status, resulting in variation between children and within the
same child for the various domains of neurodevelopment.
The impulsive and risk-taking behaviour of adolescents is also
thought to be a consequence of the interaction of social
context and the development of judgment, decision-making
and internal control [17,20].
Neuropathology caused by HIV is most evident in basal
ganglia and cerebral white matter. Neuronal loss is prominent
in the prefrontal cortical regions, which may cause difficulty
in complex mental processing [21]. These are the regions
where myelination and remodelling of synaptic connections
are still occurring during adolescence [22,23]. When coupled
with the high risk for psychiatric difficulties in PHIV
adolescents, the relationship between impaired EF and risk-
taking behaviour can be compounded.
General cognition
The most common measure of neurodevelopmental outcome
is general cognition. General cognitive assessments provide a
global score of performances in various domains. In this case,
appropriate perinatally HIV-unexposed (PHU) children can be
used as controls [12]. Neighbourhood-matched perinatally
HIV-exposed uninfected (PHEU) children can be used to
control for confounding effects of prenatal HIV exposure, ART
exposure and maternal illness, etc. [11,24], but they should
not be seen as an ideal control group.
Table 1 summarizes recent studies of general cognition in
PHIV children. Most neurocognitive assessment studies of
PHIV children have been performed in the United States
and Europe [14,2527], though some studies from other
continents have been published [1113,24]. There are many
differences between the study populations, with each group
having particular areas of vulnerability of the brain and life
experiences (e.g., higher drug abuse and lower adherence in
some parts of the United States; higher poverty and lower
access to comprehensive treatment in some limited-resource
countries; different treatment when infants). Overall, PHIV
children and adolescents perform more poorly in neurode-
velopmental assessments than PHU controls or national
norms [11,13,24], although in some studies there were no
significant differences between groups [12,26,27]. For chil-
dren in the United States, better cognitive outcomes have
been associated with having a biological parent as caregiver,
higher family income level, and higher caregiver cognitive
function [14]. In PHIV children with less severe disease
progression (WHO clinical stage I or II) and those on ART
without a history of an AIDS defining illness, overall cognitive
development has been found to be similar to that of PHEU
children [14] although still significantly poorer than PHU
children [13].
Martin and colleagues evaluated predictors of cognitive
decline in older children in the United States who had been on
ART for at least a year. Overall, PHIV children on ART remain
at risk for developing CNS disease, with children with minimal
to moderate CT brain scan abnormalities scoring significantly
lower than children with normal scans on composite mea-
sures of cognitive ability [21]. The risk in asymptomatic
adolescents was confirmed in a small pilot study which found
a higher rate of neurocognitive impairment in asymptomatic
adolescents compared to adults 60 years old (67 vs. 19%)
[28].
Few studies have addressed the effect of ART initiation on
cognitive development in PHIV school-age children and
adolescents in low- and middle-income countries. In a cohort
of Thai children, cognitive function did not improve in
response to ART, even in children who achieved virological
suppression and immunological recovery [11]. There were
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Table 1. Summary of recent studies on general cognition in HIV-infected children
Study Participants Age (range) Measure Findings Antiretroviral therapy
Koekkoek et al.
2008 [26]
The Netherlands
22 PHIV Median 9.46 years
(613.5)
SON-R No gross cognitive deficits
compared to normative values
Median age HAART initiation 5.6 years
Smith et al. 2012
USAPuerto Rico
[14]
270 PHIV/noC
88 PHIV/C
200 PHEU
716 years WISC-IV Scores significantly lower for PHIV/C group after
adjusting for covariates 77.8 vs. 83.4 and 83.3
Median age: first ART 0.6 years; first dual
therapy 1.25 years
Blanchette et al.
2002 [27]
Canada
14 PHIV
11 control
siblings
6.314 years WISC-R
or WISC-III
Mean FISQ 91.7 vs. 100.5 12 were on ART
Ruel et al. 2011
Uganda [13]
93 PHIV
106 HIV
Median 8.7 years
(612)
KABC-2 PHIV performed worse than HIV- children All children above WHO threshold for ART
initiation
Bagenda 2006
Uganda [12]
28 HIV
42 HEU
37 HIV
612 years KABC No significant difference ART-naı¨ve
Wood 2009
USA [25]
81 PHIV
38 PHIV/C
43 PHIV/noC
Median 15.2 years
(1124)
WISC-IV or WASI Median FISQ of PHIV/noC fell within normal range;
Median FISQ of HIV/C in below average range
Median age: ART initiation: 3.1 years;
Median age: HAART initiation: 6.5 years
Puthanakit et al.
2010 [11]
Thailand
39 HIV 
40  affected
42 healthy controls
Median 9.3 years
(612)
WISC-III Mean FISQ of HIV and affected groups significantly
lower than healthy controls
79 vs. 88 vs. 96 pB0.01
87% on ART for median of 35 weeks (IQR
2953)
Puthanakit et al.
2013 [29]
Thailand, Cambodia
284 PHIV, 155 PHEU,
164 PHU
Median age 9 years
(112)
WISC-Thai No difference between early and deferred ART
initiation RCT arms. PHIV children performance
worse than PHEU and PHU on IQ
Early versus deferred HAART at enrolment from
1 to 12 years of age
Hoare et al. 2012
South Africa [24]
12 PHIV
12 HIV  community
controls
812 years WASI:
verbal
performance
Mean scores:
87.8 vs. 101.2
73.7 vs. 85.7
ART-naı¨ve
PHIV/C Perinatally HIV-infected with a previous class C event.
PHIV/noC Perinatally HIV-infected with no past history of class C event.
KABC Kaufman Assessment Battery for children.
KABC-2 Kaufman Assessment Battery for children, 2nd edition.
SON-R Snijders-Oomen nonverbal intelligence test for children and adolescents (abridged).
WASI Wechsler Abbreviated Scale of Intelligence.
WISC-R Wechsler Intelligence Scale for Children Revised.
WISC-III & IV Wechsler Intelligence Scale for Children versions 3, 4. WISC-Thai Wechsler Intelligence Scale for Children Thai version.
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also similar neurodevelopmental and neuropsychological
outcomes in Thai and Cambodian children between early
and deferred ART groups, although both groups performed
worse than PHEU children [29]. A small study of younger
South African children (median age five years) also failed to
observe neurodevelopmental improvement following ART
initiation [9].
Specific domains of cognitive development
Global cognitive scores may overlook subtle deficits in one or
more areas specific to PHIV children and may affect their
performance on a different level [26,30,31]. For example, even
in PHIV children with global cognitive scores in the normal
range, EF may be impaired, especially in children with cortical
atrophy, lower fractional anisotropy of the corpus callosum
and those with CD4 counts below 500 cells/mm3 [21,24].
Specific domains may be measured as subtests on cog-
nitive assessments or by a test specifically designed for that
purpose. The development of EF starts in childhood, but is
highly important in the development of adolescents. EF is a
composite of different domains including processing speed,
response inhibition, working memory, response planning,
cognitive flexibility with task switching, attention and con-
centration [32]. Processing speed is associated with increased
capacity for working memory, enhanced inductive reasoning
and greater accuracy in solving arithmetic word problems, and
consistently predicts performance on cognitive tasks [16].
Table 2 summarizes studies that explore the impact of
HIV on important neurocognitive domains. PHIV children
have been found to perform significantly poorer in EF
tasks, particularly in terms of processing speed [13,14,26,33],
memory [12,14,21,24,34] and attention [13]. Lower scores on
visualspatial processing have also been described in younger
PHIV children [27,35].Visualspatial processing is important
for adolescents as it impacts on reading, writing and learn-
ing. PHIV children have been shown to be slower and less
accurate on pattern recognition [26], and to have lower
scores than controls on sequential processing, simultaneous
processing [36], planning/reasoning [13] and visual memory
[24].
Adaptive functioning
Adaptive functioning has been defined as the ability to
function effectively in a number of settings requiring social
and problem solving skills, including school, home and social
settings [37]. Cognitive assessments may not be the appro-
priate measurement tools to capture the ability of children
and adolescents to function in real life situations. For
example, in child-headed households in resource-constrained
settings, children are required to take far more responsibility
than in resource-rich countries. Measuring adaptive function-
ing, as previously used in younger children, may provide a
more meaningful way of assessing how adolescents are
functioning in their own environments. There is conflicting
evidence on the correlation of scores. Gosling et al. found
significant weakness in adaptive functioning compared with
cognitive functioning in PHIV children [38]. In contrast,
Smith et al. found some disparity, with higher scores in
adaptive function at lower cognitive scores [14]. As the
number of PHIV children grow, further research on this is
needed to determine whether measuring adaptive function-
ing is a useful measurement tool for neurodevelopmental
outcomes in PHIV adolescents in less developed settings.
The interplay between HIV, neurodevelopment,
behaviour and mental health
Several studies have focused on the burden of psychiatric
problems and mental health functioning impairment
in PHIV children and the interplay with EF, risk-taking
behaviour and treatment adherence.
A study in the United States observed a 25% prevalence of
mental health problems among PHIV children and adoles-
cents, well above that of the general population though
lower than the 38% rate observed in the PHEU comparison
group [39]. Caregiver characteristics (psychiatric disorder,
limit-setting problems and health-related functional limita-
tions) and child characteristics (younger age and lower IQ)
were most predictive of the occurrence of mental health
problems. Another US study documented that 18% of 617
year old PHIV children had a lifetime history of psychiatric
medications, 13% were on medication (largely stimulants
and antidepressants) for psychiatric problems and 22% had a
past or current history of non-medication psychological
intervention [40].
There is a strong association between psychological and neu-
rocognitive functioning. In a study in Atlanta and New York
City, depressive symptoms in PHIV adolescents were best
predicted by a combination of negative coping skills and poor
neuropsychological functioning. Conduct disorder problems
were directly associated with neuropsychological functioning
(cognitive inflexibility) and negative coping skills [41]. A study
in New Zealand reported that risky personality and perfor-
mance on the neuropsychological and EF tests were signifi-
cant predictors of risk-taking [42]. Furthermore, psychiatric
disorders and behavioural health challenges in PHIV
children can lead to poor ART adherence, risk-taking behav-
iour, including risky sexual behaviour, precocious sexual
debut, teenage pregnancy and substance abuse [40,4348].
These findings add weight to the increasing concern
about long-term neurodevelopmental problems among
PHIV adolescents [8,49] and the burden that these pose
for individuals, families and the education and health care
systems.
Language and hearing
As children transition to early and middle adolescence,
language and reading skills are the critical building blocks
for literacy and future academic success, with an important
transition from ‘‘learning to read and reading to learn’’ [50].
There is evidence that verbal skills are negatively affected in
PHIV children [14,24,36,50,51]. In a large study in New York
City, vocabulary and reading were worse in PHIV youths
compared to PHEU, even after adjusting for demographic
variables [50]. In contrast, Rice et al. in a multisite US
(including Puerto Rico) study found that both PHIV and
PHEU performed poorly on verbal tests, but there was no
difference between the two groups [51].
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Table 2. Specific neurocognitive domains affected in perinatally HIV-infected children
Study Participants Age (range) Measure Findings
Processing speed:
Koekkoek et al. 2008 [26]
The Netherlands
22 PHIV Median 9.5 yrs
(613.5)
Amsterdam neuro-psychological task:
baseline speed
Significantly slower compared to age-appropriate norms
Smith et al. 2012 [14]
USA Puerto Rico
88 PHIV/C
270 PHIV/NoC
200 PHEU
716 years WISC-IV
Processing speed
Lower scores on processing speed for PHIV/C compared to PHIV
/NoC and PHEU. PHIV/NoC and PHEU scores were similar
Nachman et al. 2012 [34]
USA
319 PHIV
IQ70
617 years WISC-IV coding recall Higher peak viral load (100 000 copies/ml)and lower nadir
CD4% (B15%) associated with slower speed
Ruel et al. 2012
Uganda [13]
93 PHIV
106 PHU
CD4]15%
CD4 count
]350 cells/ml
Median
8.7 yrs
(612)
Test of variables of attention Worse visual, auditory and overall reaction time than HIV-community
age matched
Set Shifting:
Koekkoek et al. 2008 [26]
The Netherlands
22 PHIV Median
9.5 yrs
(613.5)
Amsterdam Neuro-psychological task:
Attentional flexibility
Significantly slower compared to age-appropriate norms
Better outcomes with longer HAART duration
Verbal Fluency: (EF in the verbal domain)
Koekkoek et al. 2008 [26]
The Netherlands
22 PHIV Median
9.5 yrs
(613.5)
Verbal fluency Significantly lower scores compared to age appropriate norms
Hoare et al. 2012 [24]
South Africa
12 PHIV
12 HIV
Mean 10.4 yrs
(812)
Semantic fluency Significantly lower than HIV-negative controls from same
neighbourhood
Memory
Blanchette et al. 2002 [27]
Canada
14 PHIV
11 control
siblings
6.314.9 yrs WISC-digit span and information
Story recall
Rey Complex figure
No difference between groups
Bagenda 2006
Uganda [12]
28 HIV
42 HEU
37 HIV
612 years KABC Sequential processing
(Immediate memory recall)
HIV significantly lower scores than HEU
No difference between PHIV and HIV- groups
Martin et al. 2006 [21]
USA
41 PHIV Mean 11.2 yrs
(616)
WISC III  working memory:
Digit span backwards
Arithmetic
Significantly lower scores in those with abnormal CT brain scans
compared to those with normal scans
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Table 2 (Continued )
Study Participants Age (range) Measure Findings
Hoare et al. 2012 [24]
South Africa
12 PHIV
12 HIV
Mean 10.4 yrs
(812)
Working memory:
WISC IV digit span Backward
Visual memory:
Rey complex figure
Groups performed similar for working memory
Visual memory significantly worse in PHIV compared to HIV-
controls
Smith et al. 2012
USAPuerto Rico [14]
270 PHIV/noC
88 PHIV/C
200 PHEU
716 years WISC IV:
Working memory
2 to 5 fold increased risk of impairment for HIV/C group compared
to PHEU group
Visual spatial memory/integration
Koekkoek et al. 2008 [26]
The Netherlands
22 PHIV Median
9.5 yrs
(613.5)
Amsterdam neuro-psychological task: visuospatial
memory
Significantly lower scores in visuospatial working memory compared
to age-appropriate norms.
Puthanakit et al. 2013 [29]
Thailand, Cambodia
284 PHIV,
155 PHEU,
164 PHU
Median 9 yrs
(112),
Beery Visual Motor Integration No difference between early and deferred ART initiation RCT arms
PHIV children performance worse than PHEU and PHU
Hoare et al. 2012 [24]
South Africa
12 PHIV
12 HIV
Mean 10.4 yrs
(812)
Spatial processing:
WASI block design
Rey complex figure test
Significantly worse than HIV-negative controls
PHIV/C: Perinatally HIV-infected with a previous class C event.
PHIV/noC: Perinatally HIV-infected with no past history of class C event.
La
u
g
h
to
n
B
e
t
a
l.
Jo
u
rn
a
l
o
f
th
e
In
te
rn
a
tio
n
a
l
A
ID
S
So
cie
ty
2
0
1
3
,
1
6
:1
8
6
0
3
h
ttp
://w
w
w
.jia
so
cie
ty.o
rg
/in
d
e
x.p
h
p
/jia
s/a
rticle
/vie
w
/1
8
6
0
3
|
h
ttp
://d
x.d
o
i.o
rg
/1
0
.7
4
4
8
/IA
S.1
6
.1
.1
8
6
0
3
6
While CD4 cell count, HIV viral load and CDC Classification
were not associated with verbal scores in the New York City
study [50], two other US studies found that a history of
an AIDS-defining illness was associated with verbal compre-
hension impairment [14,51]. In addition, Rice et al. found
that after controlling for cognitive and hearing impairment,
children who were PHIV with detectable viral load and ART
initiation less than six months of age had an increased risk of
language impairment. Other risk factors for language impair-
ment combined with cognitive or hearing impairment were
race/ethnicity, caregiver’s education and intelligence quoti-
ent (IQ) status and having a non-biological parent as
caregiver [51].
Adjustment for hearing deficits in language assessment of
PHIV children is important as the prevalence of hearing
loss in PHIV children is high and ranges from 20% in higher
income countries to 38% in low-resource settings [52,53].
In resource-poor settings, hearing loss was largely conduc-
tive, including chronic suppurative otitis media and dry
tympanic membrane perforations, which may reflect the
lack of consistent otological care, whereas in well-resourced
settings more children had sensorineural hearing loss [54],
which may possibly be related to measurement in the United
States. A low CD4 count and a history of AIDS-defining illness
were associated with both hearing and language impairment
[53,54].
School performance
School performance is a functional outcome that is highly
relevant in terms of future quality of life and employment
prospects [55]. Academic failure predicts problems in school-
ing and leads to an increase in school dropouts [56]. Insight
into the school performance of PHIV children is important
in order to plan appropriate resources to support this
vulnerable population. However, accurate measurement is
problematic due to the abundance of potential confounders.
A child’s school performance is dependent on numerous vari-
ables including social and family factors [55,56]. In addition,
the indirect effects of HIV infection including hearing loss,
school absenteeism due to ill health or ART management,
depression and/or social problems need to be considered
when interpreting school performance [33].
Several studies have explored school performance among
PHIV children and adolescents, and identified poorer
outcomes compared with children without HIV, with the
exception of a French study, which reported an academic
failure rate of 16%, similar to the general population [57].
Outcome measurements were highly variable and included
42% with a learning disability [25], 2733% receiving special
education [50,57,58], 15% having repeated two or more
grades [57] and 51% having failed at least one grade [59].
Limited caregiver education or intelligence level increased
the risk of poor educational outcomes [14]. There is a striking
lack of studies on academic achievement in resource-limited
countries. Although such research would be difficult to
undertake, it would provide valuable information to guide
interventions.
Physical disabilities due to neurological
problems
Physical problems due to HIV encephalopathy have been well
described in the pre-ART era [10]. There is however a paucity
of data on neurological outcomes of ART-naı¨ve PHIV child
non-progressors as well as those on ART, particularly in older
children. In Uganda, Bagenda et al. describe children with
hypotonia, hyperreflexia and delayed milestones, which
disappeared as they grew older [12]. Boivin et al. also found
motor impairment in PHIV asymptomatic children in the
first two years of life and later in childhood (ages 812 years)
[36].
Two South African studies described motor deficits
and neurological manifestations in PHIV children [9,60].
Govender et al. reported 59% abnormal neurological exam-
inations in children aged one month to 12 years, 41% with
global pyramidal long tract signs and 16% with cortical visual
impairment. However, there were many participants with
neurological sequelae due to secondary infections and the
direct effects of HIV infection are not clear [60]. Smith et al.
found evidence of motor dysfunction in 33% of ART-naı¨ve
children with no improvement after six months of treatment
[9]. In a cohort of 210 PHIV French children followed
since birth, at a median age of 15 years, three children had
persistent motor dysfunction and five had mild to moderate
physical impairment, indicating a low incidence of physical
disabilities due to neurological problems in children who
gain timely access to ART [57]. Some of the neurological
manifestations in the young child may not be reversible and
may still be evident in the adolescent. We have included
these studies to emphasize that a neurological examination
should be included when measuring functional outcomes in
PHIV adolescents.
CNS disease and stroke have been documented as causes of
death in PHIV children, adolescents and young adults in the
USA [8]. In the pre-ART era, the annual risk of cerebrovascular
events was 1.3% [61], but there are no data on the incidence
of stroke in PHIV children on ART. Similarly, the incidence
and effect of central nervous system insults caused by
infections such as tuberculosis and meningitis have not
been well documented.
Markers of HIV disease progression and
severity
Traditional markers of HIV disease progression and severity
including high plasma viral load, lower CD4 cell counts
and/or CD4%, and history of an AIDS defining illness have
been associated with poorer neurocognitive performance
[13,14,21]. In addition, some markers of vascular dysfunction
and T-cell activation have been found to correlate with global
cognitive outcomes in PHIV youth. Specifically, higher
soluble P-selectin, a marker and mediator for inflammatory
vascular disease, and lower fibrinogen (a pro-coagulant state
marker) have been associated with poorer cognitive func-
tion [62]. CD4activation and, under certain circumstances,
CD8 activation have been shown to have favourable
neurodevelopmental implications in PHIV-infected children
[63]. In a study of ART-naive Ugandan children, HIV subtype-
A was associated with higher viral loads and poorer
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performance compared to subtype-D, suggesting that subtype-
A may be more neuropathogenic in children [64].
Intervention strategies
Studies have found that ART alone is not sufficient to reverse
the neurodevelopmental consequences of HIV infection
[31,65]. Highly active ART (HAART) may even contribute to
neuromotor decline over time [31,66]. The inability of ART
alone to restore HIV children to ‘‘normal’’ neuropsycholo-
gical performance is a compelling rationale to evaluate
alternative interventions for neurocognitive disability in
paediatric HIV. Despite knowledge of deficits in PHIV
children, there have been very few intervention studies. One
intervention is computerized cognitive rehabilitation training
[67,68]. Preliminary results in Uganda indicate that using
computer games for cognitive rehabilitation can be of great
benefit to PHIV children and adolescents [69]. For younger
children with HIV, caregiver training on practical strategies to
enrich the developmental milieu of these children can also
have significant neurocognitive benefit [70].
There is evidence to suggest a strong link between
psychological well-being and the immunological impact of
disease progression [71]. HIV-infected children who exhibited
signs of resilience tended to have better neurodevelopmental
functioning, socialemotional and gross motor functioning
[72]. Some approaches to fostering resilience in PHIV
children have centred around family dynamics within a
cultural framework [7376]. In a qualitative study of resi-
lience among Rwandan HIV-affected children and families
[74], Betancourt and colleagues identified five factors that
increased resilience in children and families affected by HIV:
perseverance, self-esteem/self-confidence, family unity/trust,
good parenting, and collective/communal support. Interven-
tions and strategies to leverage these resources may help to
prevent mental health problems in these children as they
grow into adolescence and adulthood [73]. Psychosocial
intervention may also significantly enhance subsequent
neurocognitive development of the child in response to the
direct physiological, psychological, social and immunological
impacts of this disease. For example, Coscia et al. showed that
home environment had a stronger association with child IQ
during the advanced than the early stages of disease [77].
Parental support has been shown to provide a stress-buffering
effect for the effects of depression in these school children,
that seemed to improve psychosocial and cognitive develop-
ment [78,79].
Discussion
Each child has their own set of unique factors that shapes
their development, making it difficult to identify the relative
contribution of different factors impacting on the neurode-
velopmental outcomes of PHIV adolescents. While HIV has
a direct effect on neurocognitive development, the effects
of deprivation and poverty, quality of home environment,
genetics, opportunistic infections, and access to care may
overshadow the effects of HIV, particularly in resource-
constrained settings.
Important variables that have been shown to affect
neurodevelopmental outcomes include caregiver mental
health or substance problems [14], orphan status and chronic
illness [60], nutritional status [60,80] formal education and
home environment [80] as well as having a biological parent
as caregiver, higher family income level and higher caregiver
cognitive functioning [14]. Given the psychosocial impact
of diagnosis and treatment, as well as the contribution of
coping with cognitive weaknesses, additional attention to
behavioural and mood symptoms associated with childhood
HIV is essential.
It is possible that ART initiation in school-aged children and
adolescents may be too late to reverse impairment. Cohorts
initiating ART earlier report better outcomes, suggesting that
earlier ART initiation is beneficial [6,29]. However, there is
inadequate evidence of the effects of long-term ART on the
developing brain. Lower nadir CD4 counts, higher viral loads
and the history of an AIDS-defining illness are associated
with poorer neurodevelopmental outcomes, further support-
ing the need for early ART initiation in children. Children
presenting with these risk factors should be offered neuro-
developmental screening as part of routine HIV care and
referral to supportive services or formal assessments where
appropriate. PHIV adolescents should be provided with
multidisciplinary support services including adherence sup-
port, reproductive health counselling and mental health and
educational/vocational planning [81]. Preliminary evaluations
of these multi-faceted interventions for PHIV adolescents
have shown good results in improving adherence and reduc-
ing risk-taking behaviours [8184].
While most studies describe the proportions of male and
female study participants, generally the data were not
analysed and compared for sex differences in outcomes.
This is possibly because it is generally accepted that the
neurodevelopment of boys and girls are similar. However,
possible sex differences in adolescent neurodevelopmental
outcomes require further exploration.
Conclusions
PHIV adolescents constitute a large heterogeneous popu-
lation. Overall, HIV children and adolescents have poorer
neurodevelopmental outcomes than uninfected peers, parti-
cularly those with more advanced HIV disease. There is also
emerging evidence that PHIV adolescents are especially at
risk for poorer psychiatric outcomes and EFs. However, the
impact of HIV on the developing adolescent brain is highly
complex, influenced by many factors and not well under-
stood. Compounding and contributory factors may include an
increased risk of substance use, risky sexual and other risk-
taking behaviours, and poorer ART adherence.
A striking finding is the paucity of data specific to the
adolescent age group (1025 years) and the lack of long-
itudinal cohort studies designed to assess the effect of HIV on
neurocognitive functioning in PHIV adolescents. While
much of the current evidence is from younger ages, evidence
from these studies provides valuable information as neuro-
developmental problems occurring at younger ages are likely
to persist in adolescence and adulthood. Furthermore, the
majority of studies on neurodevelopmental outcomes in
adolescents are from the United States and Europe, with few
studies from low- and middle-income countries which have
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the highest prevalence of PHIV adolescents. Few studies
explore possible gender differences in adolescent neurode-
velopment. Finally, little is known about the complex nature
of recovery of the brain after initiation of ART. Thus, there
is an urgent need for longitudinal research assessing the
long-term effect of ART and timing of ART initiation on
neurodevelopmental outcomes of perinatally HIV-infected
adolescents by gender, particularly in resource-constrained
settings.
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